CA-LAMBDATEST
6.3.2023 17:01:36 CET | Business Wire | Press release
LambdaTest, the leading digital experience testing cloud platform, has partnered with LinkedIn to offer the LambdaTest Test Automation Professional Certificate exclusively available on LinkedIn Learning, as part of its mission to support the testing and QA community.
Through this Professional Certificate course, learners will acquire fundamental knowledge of test automation, including various tools and best practices, in a highly engaging manner from Meaghan Lewis, Technical Program Manager at Microsoft.
More importantly, learners will be able to implement and optimize test automation in their jobs after this course. To earn their LambdaTest Test Automation Professional Certificate, learners will have to complete all courses and content in the learning path and pass the final exam. Learners can access their certificates immediately after they pass the final exam and seamlessly showcase their certificate on LinkedIn.
"We are excited to partner with LambdaTest to provide our customers and learners additional, credible paths to upskilling as well as broaden the audience for the LambdaTest Test Automation Professional Certificate to the world’s largest talent marketplace," said Dan Brodnitz, Sr. Director of Global Content Strategy at LinkedIn Learning.
As LinkedIn Learning students for the LambdaTest Test Automation Professional Certificate, learners can get free trial access to the LambdaTest platform. This enables learners to get hands-on experience and implement the concepts.
“Enterprises, all over the world, are automating their testing to ensure a better digital experience for their users. Learning test automation will open up various career avenues for learners. We are also happy to offer free access to the LambdaTest platform to enable students to get hands-on experience. We are excited to play our role in enabling thousands of learners to achieve their career goals,” said Maneesh Sharma, Chief Operating Officer, LambdaTest.
LambdaTest recently announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
Also, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/certifications/linkedin-learning
Notes to the editor
For further information please contact the LambdaTest press office: press@lambdatest.com.
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
● Cross Browser Testing Cloud
LambdaTest test execution platform allows users to run both manual and automated tests across 3000+ different browsers, real devices, and operating system environments. It enables developers to test their websites, web applications, and native apps without requiring to install or maintain an internal lab of virtual machines, real devices, emulators, or simulators.
● Real Device Testing Cloud
With LambdaTest’s Real Devices Testing Cloud, you can now test unhandled errors, UI/UX, performance, and functionality of your native, web, and hybrid apps before they get released into production. Test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV). With seamless cross-functional team collaboration across the mobile app development lifecycle, you can release quality mobile apps in shorter development cycles which enables you to innovate and scale rapidly.
● Continuous Testing Cloud - HyperExecute
An IP-led next-gen cloud test execution and orchestration platform that helps enterprises run end-to-end automation tests at the fastest speed possible, thereby enabling them to achieve quicker time-to-market, and deliver a quality digital experience. Achieve 70% faster test execution times and zero flakiness with HyperExecute.
● Visual Regression cloud
Perform Regression Testing in just one click using LambdaTest. Compare the screenshots of your application’s webpages taken from two different browsers to view/detect any visual deviations. Increase browser coverage by running automation scripts on a cloud of 3000+ different desktop and mobile environments.
● Test Intelligence at Scale
Test execution insights are critical for digital transformation as they provide enterprises with more profound insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's Integrated Test Intelligence delivers enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom